Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | VCP | P55072 | 4/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361637 | 1.00 | KMT2A (0.54) | KMT2AEPHX2FABP5FABP7CYP2C19 | |
| SCHEMBL30309102 | 1.00 | KMT2A (0.54) | KMT2AEPHX2FABP5FABP7CYP2C19 | |
| SCHEMBL31693430 | 1.00 | KMT2A (0.54) | KMT2AEPHX2FABP5FABP7CYP2C19 | |
| SCHEMBL800277 | 1.00 | KMT2A (0.54) | KMT2AEPHX2FABP5FABP7CYP2C19 | |
| SCHEMBL4652253 | 0.99 | KMT2A (0.53) | KMT2AEPHX2FABP5FABP7CYP2C19 | |
| SCHEMBL13020981 | 0.92 | KMT2A (0.57) | KMT2AEPHX2FABP5FABP7CYP2C19 | |
| SCHEMBL30759367 | 0.89 | KMT2A (0.55) | KMT2AEPHX2FABP5FABP7OPRD1 | |
| SCHEMBL22197915 | 0.89 | KMT2A (0.55) | KMT2AEPHX2FABP5FABP7OPRD1 | |
| SCHEMBL27041463 | 0.89 | KMT2A (0.55) | KMT2AEPHX2FABP5FABP7OPRD1 | |
| SCHEMBL27041477 | 0.89 | KMT2A (0.55) | KMT2AEPHX2FABP5FABP7OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116655516-A | Compound for prostate cancer specific fluorescent probe, preparation method and application thereof | 中国医学科学院肿瘤医院深圳医院 | 2023-08-29 | — | — | CN | claimed |
| US-20260069725-A1 | LIGAND COMPOUND TARGETING PSMA ANTIGEN, AND CHELATE AND USE THEREOF IN DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Chengdu StarRay Therapeutics Co., Ltd (CN) | 2026-03-12 | — | — | US | disclosed |
| EP-4696680-A1 | DUAL-FUNCTIONAL TETRAZINE COMPOUNDS FOR VERSATILE RADIOLABELING WITH RADIOMETALS AND RADIOHALOGENS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | Tetrakit Technologies ApS (DK) | 2026-02-18 | — | — | EP | disclosed |
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | TRUSTEES OF TUFTS COLLEGE | 2026-01-08 | — | — | US | disclosed |
| US-20260007784-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2026-01-08 | — | — | US | disclosed |
| US-20250073358-A1 | AROMATIC VINYL COMPOUND, METAL COMPLEX THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2025-03-06 | — | — | US | disclosed |
| WO-2025037024-A1 | PSMA THERANOSTIC COMPOUNDS ASSEMBLED WITH TETRAZINE-TRANS-CYCLOOCTENE LIGATION | UNIVERSITY OF COPENHAGEN (DK) | 2025-02-20 | — | — | WO | disclosed |
| EP-4509145-A1 | PSMA THERANOSTIC COMPOUNDS ASSEMBLED WITH TETRAZINE-TRANS-CYCLOOCTENE LIGATION | University of Copenhagen (DK) | 2025-02-19 | — | — | EP | disclosed |
| US-20240382631-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2024-11-21 | — | — | US | disclosed |
| EP-4455131-A1 | AROMATIC VINYL COMPOUND, METAL COMPLEX THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Maxinovel Pharmaceuticals Co., Ltd. (CN) | 2024-10-30 | — | — | EP | disclosed |
| US-20060018830-A1 | Gastrin releasing peptide compounds | BRACCO IMAGING S.P.A. (IT) | 2006-01-26 | — | — | US | disclosed |
| EP-1604647-A1 | Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof | Ichimaru Pharcos Co., Ltd. (JP) | 2005-12-14 | — | — | EP | disclosed |
| EP-1602354-A1 | HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR | Meiji Seika Kaisha, Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
| EP-1423373-B1 | SUBSTITUTED AMIDES, SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY | AVENTIS PHARMA INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040253225-A1 | bombesin, derivatives and/or analogues capable of complexing metal ions, radionuclides or optical labels, for use in radiotherapy | BRACCO IMAGING S.P.A. (IT) | 2004-12-16 | — | — | US | disclosed |
| US-20040204582-A1 | Substituted sulfonamides and ureas useful for inhibiting kinase activity | AVENTIS PHARMACEUTICALS INC. | 2004-10-14 | — | — | US | disclosed |
| US-6777577-B2 | ANTICANCER AGENTS; ANTIDIABETIC AGENTS, ANTICHOLESTEROL AGENTS, CARDIOVASCULAR DISORDERS, OSTEOPOROSIS | AVENTIS PHARMACEUTICALS INC. | 2004-08-17 | — | — | US | disclosed |
| US-20040136906-A1 | Gastrin releasing peptide compounds | BRACCO IMAGING S.P.A. (IT) | 2004-07-15 | — | — | US | disclosed |
| US-20030087832-A1 | Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity | AVENTIS PHARMACEUTICALS INC. | 2003-05-08 | — | — | US | disclosed |
| US-20030045480-A1 | Method of treating hyperresorptive bone disorders | ARIAD PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204582-A1 | Substituted sulfonamides and ureas useful for inhibiting kinase activity | CHUK, SRC, DSTYK | KMT2A 1104/4885EPHX2 3953/4885FABP5 2904/4885 |
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | FIBP, FRS2, FGFR1 | KMT2A 3715/4885EPHX2 2207/4885FABP5 721/4885 |
| US-20240382631-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | KLK3, FOLH1, PSMA1 | KMT2A 2664/4885EPHX2 2835/4885FABP5 57/4885 |
| US-20250073358-A1 | AROMATIC VINYL COMPOUND, METAL COMPLEX THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CD274, PDCD1, PDCD1LG2 | KMT2A 1400/4885EPHX2 4772/4885FABP5 2216/4885 |
| US-20040253225-A1 | bombesin, derivatives and/or analogues capable of complexing metal ions, radionuclides or optical labels, for use in radiotherapy | GRPR, MLNR, NPBWR1 | KMT2A 4045/4885EPHX2 3747/4885FABP5 1306/4885 |
| US-20030045480-A1 | Method of treating hyperresorptive bone disorders | SRC, GRB2, ACP1 | KMT2A 1735/4885EPHX2 4196/4885FABP5 948/4885 |
| US-20060018830-A1 | Gastrin releasing peptide compounds | GRPR, GIPR, CCKBR | KMT2A 2523/4885EPHX2 3656/4885FABP5 197/4885 |
| US-20260007784-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | KLK3, PSMA1, ACP3 | KMT2A 1063/4885EPHX2 2600/4885FABP5 648/4885 |
| US-20260069725-A1 | LIGAND COMPOUND TARGETING PSMA ANTIGEN, AND CHELATE AND USE THEREOF IN DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | KLK3, PSMA1, FOLH1 | KMT2A 645/4885EPHX2 4556/4885FABP5 255/4885 |
| US-20030087832-A1 | Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity | SRC, CHUK, DSTYK | KMT2A 693/4885EPHX2 3914/4885FABP5 2632/4885 |
| US-20040136906-A1 | Gastrin releasing peptide compounds | GRPR, GIPR, MLNR | KMT2A 4142/4885EPHX2 3641/4885FABP5 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.